Overview

Salvage Immunotherapy and Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy

Status:
Not yet recruiting

Trial end date:
2024-09-30

Target enrollment:

Participant gender:

Summary

This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of esophageal squamous cell carcinoma patients nonresponding to initial neoadjuvant chemoradiotherapy. The purpose of this study was to evaluate the efficacy and safety of immunotherapy combined with chemotherapy in the adjuvant treatment of esophageal squamous cell carcinoma after surgery.

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Chest Hospital

Treatments:

Cisplatin
Fluorouracil
Immune Checkpoint Inhibitors
Pembrolizumab